G. A. Rassadina

  • Citations Per Year
Learn More
The following markers of inflammation: enzymatic activity of leukocyte elastase (LE), functional activity of alpha-1-proteinase inhibitor (α1-PI), levels of C-reactive protein (CRP) and interleukin-6 (IL-6) were measured in the blood plasma of patients with Alzheimer's disease (AD) and vascular dementia (VD). The results confirm the presence of an(More)
To assess efficacy and safety of 4-month therapy with rivastigmine in Alzheimer's disease (AD) and to evaluate the burden of caregivers to these patients, 25 AD patients have been studied. Rivastigmine was prescribed internally and 22 patients were assigned to additional antipsychotic therapy at the admission to the hospital. The treatment duration was 16(More)
The efficacy and safety of four-month courses of rivastigmine and changes in measures of carer burden were studied in a non-randomized group of 25 patients with Alzheimer’s disease (AD). All patients received p.o. rivastigmine and 22 patients received antipsychotic therapy along with rivastigmine on admission. Treatment was continued for 16 weeks (12 weeks(More)
  • 1